Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for SUPN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -4.81M
March 31, 2026 66.52M
December 31, 2025 19.86M
September 30, 2025 -61.66M
June 30, 2025 58.54M
March 31, 2025 30.60M
December 31, 2024 44.41M
September 30, 2024 53.52M
June 30, 2024 35.62M
March 31, 2024 38.40M
December 31, 2023 44.96M
September 30, 2023 35.88M
June 30, 2023 -18.87M
March 31, 2023 49.13M
December 31, 2022 27.56M
September 30, 2022 13.84M
June 30, 2022 71.12M
March 31, 2022 4.302M
December 31, 2021 48.76M
September 30, 2021 -4.11M
June 30, 2021 46.27M
March 31, 2021 36.20M
December 31, 2020 31.93M
September 30, 2020 5.599M
June 30, 2020 91.95M
Date Value
March 31, 2020 8.916M
December 31, 2019 43.79M
September 30, 2019 37.66M
June 30, 2019 28.69M
March 31, 2019 32.99M
December 31, 2018 32.85M
September 30, 2018 62.45M
June 30, 2018 6.556M
March 31, 2018 27.13M
December 31, 2017 36.34M
September 30, 2017 39.00M
June 30, 2017 25.94M
March 31, 2017 13.36M
December 31, 2016 24.94M
September 30, 2016 28.24M
June 30, 2016 16.78M
March 31, 2016 -3.142M
December 31, 2015 22.34M
September 30, 2015 -0.523M
June 30, 2015 12.98M
March 31, 2015 -0.265M
December 31, 2014 6.994M
September 30, 2014 26.78M
June 30, 2014 -6.94M
March 31, 2014 -19.10M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Indivior Pharmaceuticals, Inc. 228.52M
Pfizer Inc. 835.00M
Amphastar Pharmaceuticals, Inc. 51.32M
Collegium Pharmaceutical, Inc. 71.32M
Bristol Myers Squibb Co. 3.393B